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Abstract
As per the current scenario, the role of transcatheter aortic valve implantation (TAVI) is controversial in 
bicuspid aortic valve (BAV) stenosis. All the randomized clinical trials comparing outcomes of TAVI with 
surgery, till date, have excluded patients with the BAV. Some of the observational studies have reported 
outcomes of TAVI in BAV stenosis patients who are not a surgical candidate. The recent advances in TAVI and 
its expansion into intermediate groups, which includes younger age groups sparks a debate on the efficacy 
and safety of TAVI in BAV. The purpose of the present article is to review the available literature regarding 
the feasibility, safety, and outcomes of TAVI in BAV stenosis.
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Case Report
Eighty-five year-old female patient with the medical 
history of diabetes, hyperlipidemia on statins, and 
chronic atrial fibrillation on Coumadin was referred to 
our institute for severe symptomatic aortic stenosis. 
She endorses that her condition has deteriorated 
over past year. She started noticing lower extremity 
swelling, two pillow orthopnea and fatigue on 
exertion. Echocardiogram at our institute showed 
severe aortic stenosis with a peak velocity of 4.1 m/sec, 
peak gradient 67, mean gradient 39 mmHg, and AVA 
0.8 cm2. It was not clear that the patient has bicuspid or 
tricuspid aortic valve from the echocardiogram. After 
heart team discussion, it was decided that the patient 
is not a candidate for open surgical valve replacement 
because of her age and frailty. CT scan showed done as 
a part of TAVI work up showed: Bicuspid aortic valve.
Introduction
Bicuspid aortic valve (BAV)
BAV is defined as a spectrum of abnormal aortic 
valve morphology which consists of two functional 
cusps with <3 zones of parallel apposition between 
cusps.[1] BAV is a common congenital disorder found 
in adults at a rate of 0.5–2% with a predilection 
towards males,[2-4] with a demonstrated association 
with mutations in the NOTCH1 gene.[5] Interestingly, 
its heritability is as high as 89%, suggesting an 
autosomal dominant pattern of inheritance.[6-8]
Individuals with BAV are prone to develop aortic 
stenosis (AS) at an earlier age when compared 
to people with tricuspid aortic valve (TAV). 
Nonetheless, bicuspid valves also pose a risk of 
developing symptomatic AS in elderly patients.[9] In 
fact, it is observed that its frequency is as high as 6% 
of the population over 85 years of age.[10]
Approximately 20–50% of the patients with a BAV 
require aortic valve replacement in their lifetime.[11] 
BAS is generally treated with surgical aortic valve 
replacement (SAVR) in patients <70 years of age.[9] 
However, SAVR may not be a treatment option for 
patients with high surgical risk due to comorbidities 
or in the presence of absolute contraindications 
such as porcelain aorta (extensively calcified 
ascending aorta and/or aortic arch). Even though 
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percutaneous balloon valvuloplasty can be an option 
in this population, AS reoccurs in the majority of the 
patients in the long-term.[12,13]
Transcatheter aortic valve implantation (TAVI)
TAVI is a minimally invasive procedure in which 
a new bioprosthetic (self-expandable or balloon-
expandable) valve is inserted through catheter 
delivery system and implanted into aortic valve 
position without removing the old and diseased 
valve.[14] Once the new valve is placed and expanded, 
it pushes the old valve leaflets from the site, and the 
tissue in the replacement valve takes over the job of 
regulating blood flow.
TAVI is performed through different approaches: 
Transfemoral, transapical, subclavian, direct aortic, 
and transcaval.[14] Current ACC/AHA guidelines 
recommend TAVI as Class I for patients with 
prohibitive and high surgical risk(with a post-TAVR 
survival greater than 12 months), whereas Class II 
for patients with intermediate surgical risk.
The recent advances with the valve design, TAVI is 
being studied in lower-risk populations as well as to 
treat other disease states such as BAS, native aortic 
valve regurgitation, and failed bioprosthetic aortic 
valve stenosis.[15]
BAV Anomaly, Associated Complications
BAV anomaly has several variants. BAV without 
any unwanted tissue generally develops stenosis, 
whereas valves with unwanted tissue usually tend 
to develop valvular incompetence.[16]
AS is one of the most important complications 
of BAV and its incidence on autopsy ranges from 
15% to 75%.[17] Stenosis in BAV progresses with 
age, with fibrosis beginning in the second decade 
and calcification after the fourth decade. Among 
octogenarians and nonagenarians, who underwent 
SAVR, 22% and 18%, respectively, were observed to 
have BAV.[9]
The most popular BAV classification was described 
by Sievers et al. in 2007. They identified three major 
types of BAV based on the number of raphae:
1. Type 0 – No raphe
2. Type 1 – One raphe
3. Type 2 – Two raphe.
They further subdivided these types into two 
subcategories based on:
1. Spatial arrangements of the cusp free edges 
(for example, BAV type 1 L/R means one raphe 
positioned between the left and right coronary 
sinuses)
a. Type 0 – lateral and anterio-posterior
b. Type 1- L-R, R-N, and N-L
c. Type 2 – L-R/R-N.
(L = left coronary cusp, R = Right coronary cusp, and 
N = Non coronary cusp)
2. Functional status – predominant insufficiency 
(I), predominant stenosis (S), balanced 
insufficiency and stenosis (B), and no 
insufficiency and stenosis (No)
Most patients in the study had BAV Type 1 (88%) 
predominantly L-R, S category.[1]
Bicuspid aortopathy (i.e., dilation of any part or 
all segments of the proximal aorta from the aortic 
root to the aortic arch) is the most common non-
valvular finding found in approximately 50% of 
the affected patients.[3,18] Abnormal dilation of the 
ascending aorta is generally found secondary to the 
abnormalities of the aortic media and becomes of 
significant surgical interest when the diameter of 
the aorta exceeds 4.5 cm.[18] Aortic media changes 
are present independent of the valve functionality 
(normal, stenotic, or incompetent). The pathology of 
ascending aorta is considered to be an expression of 
the genetic basis of BAV and may signify the use 
of surgical intervention.[4]
Current Management Scenario
At present, echocardiography is the most important 
and common imaging modality used with regard 
to diagnosis and surveillance. Transthoracic 
echocardiography (TTE), when compared to 
surgical operative records or surgical pathology, 
demonstrated a specificity of 96% and sensitivity of 
78% for the diagnosis.[19] One study with multiplane 
transesophageal echocardiogram (TEE) and 
operative records observed a sensitivity of 87% and 
a specificity of 91%.[20] Furthermore, pre-operative 
echocardiography and intraoperative TEE are crucial 
not only for planning the surgical approach but also, 
assessing repair status, respectively, when valve 
repair is considered for BAV regurgitation.[21]
Because echocardiography is generally diagnostic, 
but it is limited by patient and operator related 
factors. Especially in the setting of heavy 
calcification, echocardiography can be challenging 
due to artifacts. Multidetector CT (MDCT) and 
magnetic resonance imaging (MRI) are emerging as 
alternatives for the diagnosis of the BAV.
Tanaka et al. reported a sensitivity of 94% and 
specificity of 100% for ECG gated MDCT in detecting 
BAV.[22] Cardiac MRI could also play an important 
role. A recent article reported a specificity of 
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95% and sensitivity of 100% with steady-state 
free-precession cine MRI in the correct classification 
of a valve as bicuspid.[23]
With regard to treatment options, there is a recent 
emergence of new data suggesting that medical 
therapy may help in slowing down the progression 
of expansion and dissection in patients with BAV 
and aortic aneurysm.[21] Moreover, beta-blocker 
treatment now has been recommended as a Class 
IIa for BAV patients with an enlarged aorta.[24] 
Angiotensin receptor blockade is also a Class IIa 
recommendation to reduce the dilatation of the 
aorta.[25]
However, SAVR currently remains the gold standard 
of treatment for patients with BAS <70 years of age.[9] 
2010 Guidelines for the Diagnosis and Management 
of Patients with Thoracic Aortic Disease suggested 
surgery as a Class I recommendation in patients 
with genetic syndromes which could possibly lead to 
aortic dissection and BAV, at aortic diameters from 
4 to 5 cm.[25] However, surgical method has its own 
limitations where it cannot be done, for example, 
porcelain aorta (extensively calcified ascending 
aorta and/or aortic arch), hostile chest (patients 
with a history of sternotomy or radiation) or in 
patients who are suffering from comorbidities.[12,13] 
Percutaneous aortic balloon valvotomy is of limited 
use due to high recurrence rates.[12]
The latest method, which is in growing in popularity 
for its ability to treat patients who are at high or 
prohibitive risk for surgery is TAVI.
Should TAVI be used in BAV?
Treatment of BAV disease with TAVI is yet considered 
as an off-label indication. Most randomized clinical 
trials have excluded patients with BAV stenosis. The 
specific concerns regarding TAVI for BAV include:
1. The asymmetry and heavy calcification 
involving the leaflets can prevent the valve 
from expanding properly, which might result 
in a para-valvular leak and high transvalvular 
gradients.
2. The elliptical annular anatomy of a BAV may 
lead to valve malpositioning.[26]
3. There is a risk of severe aortic regurgitation due 
to the disruption of the fused commissures.
4. The concomitant aortic disease increases the 
chances of rupture or dissection during the 
procedure.
5. Finally, if a valve is malpositioned or under 
expanded due to the above-mentioned 
challenges, it affects its long-term durability.
The bicuspid valves which are surgically excised 
typically demonstrate leaflet fusion (raphe) and 
extensive nodular calcification. The morphological 
distribution of calcific deposits in BAV leaflets 
is different as compared to that of tricuspid AS 
(TAS).[27] As mentioned above, the extensive 
calcium deposition in the body of BAV leaflets and 
asymmetrical nature of the bicuspid aortic root 
could impair TAVI outcomes.[1,28]
In a retrospective study conducted by Mylotte 
et al.,[29] they have noticed that Guidewire crossing 
and transcatheter heart valve (THV) positioning 
were more difficult with bicuspid than TAV stenosis. 
However, the procedural results were acceptable 
and comparable to those reported in TAVI with 
TAS.[30-35] The acute valve embolization occurred 
in 2.2% and conversion to SAVR occurred in 2.2%, 
whereas the 30-day rates of VARC-defined device 
safety (79.1%), efficacy (84.9%), and success (89.9) 
were encouraging as well.
However, there are very few studies done in the 
past which support the use of TAVI in BAS. The first 
description of TAVI procedure in the BAV population 
was done and published by Wijesinghe et al., and 
it included 11 high-risk patients who were treated 
with a balloon-expandable prosthesis (Edwards-
SAPIEN [Edwards Lifesciences, Irvine, California]). 
The mean age was 73.2 ± 12.5 and predicted the 
risk of mortality (PROM) was 4.4 ± 2.6% according 
to the Society of Thoracic Surgeons score. TAVI was 
performed through the transfemoral (63.4%) or 
transapical route (36.4%) under general anesthesia. 
After the implantation, 18% of the patients had a 
moderate perivalvular leak (PVL), and the 30 days 
mortality was 18%. At follow-up (median time: 208 
days) mortality rate was found out to be 36.4%, 
which was mainly driven by deaths occurring in the 
transapical group in which all four patients died. 
At follow up, all survivors at follow-up were either 
in Class I or Class II of New York Heart Association 
(NYHA). Limited by only one type of bioprosthesis, 
this study for the first time showed that TAVI in BAV 
is feasible in a selected group of patients.[36]
Yoon et al. in 2016 reported clinical outcomes of 
TAVI in BAS with regard to early and new-generation 
devices in the multicenter bicuspid TAVI registry. 
This registry enrolled 301 consecutive patients 
undergoing TAVI for BAS which included 199 
patients (71.1%) receiving early-generation devices 
(Sapien XT [Edwards Lifesciences, Irvine, California]: 
n = 87; and CoreValve [Medtronic, Minneapolis, 
Minnesota]: (n = 112) and 102 patients (29.9%) 
receiving new-generation devices (Sapien 3 
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[Edwards Lifesciences]: n = 91; and Lotus [Boston 
Scientific, Marlboro ugh, Massachusetts: (n = 11). 
Mean age in the studied group was 77.0 ± 9.2 
years, and the Society of Thoracic Surgeons score 
was 4.7 ± 5.2, which classified the population 
as intermediate surgical risk group.[37] They also 
provided a comparison between the old and new 
generation devices, showing the superiority of 
new-generation over old-generation devices for 
the treatment of BAS (device success 92.2% vs. 
80.9%; P = 0.01, and second valve implantation 
1% vs. 6.5%; P = 0.04). All-cause mortality rates 
were 4.3% at 30 days and 14.4% at 1 year, which 
was comparable to that of TAVI for TAS in the 
general population. Moreover, there were no 
reported cases of moderate-to-severe paravalvular 
regurgitation with new-generation devices 
(Sapien 3 [Edwards Lifesciences] and Lotus [Boston 
Scientific, Marlborough, Massachusetts]) while 
the old generation devices had an incidence rate 
of 8.5% (Sapien XT [Edwards Lifesciences, Irvine, 
California]: n = 5 (5.7%); and CoreValve [Medtronic, 
Minneapolis, Minnesota]: n = 12(1)). These results 
from Yoon et al. offered a reassurance that TAVI 
may indeed be a reasonable treatment option for 
such patients.[37]
Himbert et al. conducted a study to assess the 
results of TAVI in BAV with self-expandable valve 
Medtronic CoreValve system (MCS; Medtronic, 
Inc., Minneapolis, Minnesota) in which 15 patients 
with a mean age of 80 ± 10 and high mortality risk 
(Society of Thoracic Surgeons score 8 ± 5) were 
evaluated. The transfemoral approach was used 
in all except for one patient, and three procedures 
were performed under general anesthesia, which 
gave access for periprocedural trans-esophageal 
guidance. Although six patients required permanent 
pacemaker implantation (40%), moderate PVL 
was seen only in one patient (6.7%) and 30 days 
survival rate was 93%. After a mean follow-up of 
8 ± 7 months, two patients were dead (13%), and 
the survivors (78.6%) achieved an improvement 
in their functional status according to NYHA I or II. 
The results of this observation suggest that BAV 
can be also safely treated with a self-expandable 
prosthesis. However, a major disadvantage an 
absence of a control group (patients with tricuspid 
anatomy) and population size.[38]
The above issue was addressed in the next studies. 
Hayashida et al. compared the results of TAVI 
obtained in 21 BAV cases with the results achieved 
in 208 patients with a normal tricuspid valve. They 
only included patients who also underwent MDCT 
before TAVI along with other imaging modalities 
(TTE and TEE). However, no statistically significant 
differences were found between the groups in 
age, sex, and mortality risk. Similar results were 
observed in terms of 30 days mortality and 
moderate/severe PVL (4.8% vs. 8.2%; P = 1.00, and 
19.0% vs. 14.9%; P = 0.54, respectively).[39]
In a similar study by Costopoulos et al., comparing 
BAV (n = 21) and TAV patients (n = 447) treated with 
Edwards or CoreValve bioprosthesis from November 
2007 to December 2012, a difference in 30 days 
mortality and 1-year mortality (14.2% vs. 3.6%, 
P = 0.02) and 10.5% vs. 7.4%, P = 0.62, respectively) 
was observed. The researchers concluded that even 
though TAVI in BAV patients with high surgical risk 
is feasible with acceptable mid-term outcomes, 
a careful selection of patients is necessary as 
patients with BAV showed lower early survival 
rates and device success. The reasons are mainly 
anatomic challenges posed by BAV patients. They 
have encountered one case of dissection, one case 
of valve migration, but the most common problem 
they encountered was a need for frequent post-
dilatation in BAV group (52.4% vs. 23.5%, P < 0.01). 
This could be due to the asymmetric calcification 
seen BAV patients. This study is limited by its small 
sample size to draw any real-world long-term 
conclusions.[40]
Subsequently, in a sub-analysis of the German Aortic 
Valve Registry (GARY), a higher rate of PVL was 
reported amongst 38 BAV patients when compared 
with a large control group of 1357 TAV patients 
(25% vs. 15%; P = 0.05) which they attributed to the 
anatomic features of a BAV.[41]
In 2014–15, two relatively large, multicenter 
studies were carried out on TAVI in BAV. One of 
them was conducted by Mylotte et al., in which 
139 BAV patients were included, and the procedural 
outcomes were evaluated for both self- and 
balloon-expandable bioprosthesis. The mean 
age of the patients enrolled was 78.0 ± 8.9 years, 
and the mean Society of Thoracic Surgeons (STS) 
PROM score was 4.9 ± 3.4%. A balloon-expandable 
THV (Sapien XT, Edwards Lifesciences, Inc., Irvine, 
California) and self-expandable THV (CoreValve, 
Medtronic, Inc., Minneapolis, Minnesota) were 
used in 48 patients (34.5%) and 91 patients (65.5%), 
respectively. Interestingly, the rate of moderate/
severe PVL in the studied group was 28.4% but was 
17.4% in the subgroup in which valve size was based 
on MDCT. A trend toward a higher rate of relevant 
PVL in patients treated with a self-expandable valve 
(19.6 vs. 32.2; P¼0.11) was observed, but as per the 
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authors, it could be because of lower use of MDCT 
for valve sizing in this group. This study emphasizes 
on patient selection and pre-procedural imaging for 
better outcomes, especially in BAV.[29]
The other study was by Yousef et al., which looked 
into the outcomes of TAVI in 108 BAV patients. 
This study also confirmed the general feasibility 
and acceptable clinical outcomes of TAVI in BAV, 
in spite of the fact that a relatively high rate of re-
intervention was seen (9.3%) because of either 
valve embolization or migration.[42]
The study conducted by Perlman et al., in 2016, 
it was concluded that TAVI in BAS using a new-
generation device (SAPIEN 3) was feasible and 
effective. Furthermore, valve performance was 
favorable, and no cases of moderate or severe AR 
were observed. This again was attributed to pre-
procedural CT annular sizing which was used to 
select an appropriately sized implant. The lack of 
significant PVL (>mild) could also be attributed to 
the improved sealing properties of the external 
sealing layer of the inflow portion of the SAPIEN 3 
valve and improvements in the accuracy of valve 
positioning with an improved valve delivery system. 
In the study, 51 patients underwent TAVI using 
the SAPIEN 3 valve. The mean age in the patient 
group was 76.2 ± 9.3 years, and the predicted risk 
of mortality scores was 5.2 ± 3.7% according to the 
Society of Thoracic Surgeons. The most common 
bicuspid valve type was type 1 (82.3%) followed by 
type 0 (11.8%) and type 2 (1.9%). Post-dilation was 
performed in 7.8% of the cases. There were no cases 
of valve embolization or need for a second valve. 
The mean aortic gradient decreased from 49.4 ± 
16.0 mm Hg to 11.2 ± 4.7 mm Hg. Post-implantation 
AR was mild in 37% and none/trivial in 63%. There 
were no cases of moderate or severe AR. At 30 
days follow-up, 2 deaths (3.9%), two major vascular 
complications were observed with 12 patients 
(23.5%) requiring pacemaker implantation.[43]
The results of a recent international multicenter, 
observational study comparing outcomes of TAVI 
in bicuspid versus TAV were presented at the 
American college of cardiology conference. Here 
researchers compared outcomes of 561 patients 
with bicuspid AS and 4546 patients with TAS after 
propensity-score matching; assembling 546 pairs 
of patients with similar baseline characteristics. 
The study found that when compared to patients 
with TAS, patients with BAS had more frequent 
conversion to surgery (2.0% vs. 0.2%; P = 0.006) 
and significantly lower device success rate (85.3% 
vs. 91.4%; P = 0.002). Interestingly in these study 
early-generation devices (Sapien XT, CoreValve) 
were implanted in 320 patients with bicuspid and 
321 patients with TAS, whereas new-generation 
devices (Sapien 3, Lotus, Evolut R) were implanted 
in 226 and 225 patients with bicuspid and TAS, 
respectively.
The early generation devices had a high incidence 
of moderate to severe PVL (15.4%), whereas the 
incidence was low and comparable to TAS with 
newer generation devices (2.7%). Among the 
early generation devices, the CoreValve had more 
moderate-to-severe PVL (19.4% vs. 10.5%, P = 0.02). 
Among the BAS patients receiving early-generation 
devices, Sapien XT had more frequent aortic root 
injury (4.5% vs. 0.0%, P = 0.015). They concluded that 
TAVI in BAS was associated with similar prognosis 
but higher adverse procedural events compared 
to TAS. However, there were no differences with 
the new generation devices. The patients with 
newer-generation devices had acceptable and 
comparable procedural results to trisuspid TAVI and 
this was similar across different prostheses. The 
cumulative all-cause mortality rates at 2 years were 
comparable between bicuspid and TAS (17.2% vs. 
19.4%, P = 0.28). The important finding of the study 
is that TAVI is feasible with certain BAS patients 
with newer generation valves (Sapien 3, Lotus, 
Evolut R).[44]
These studies are compared in Table 1. With the 
advancement of technology, it seems that TAVI 
can indeed be technically feasible in selected BAV 
patients, especially with the newer generation 
valves. However, a meticulous preprocedural 
assessment and planning are needed for better 
outcomes.
Role of Pre-procedural Imaging in BAV 
TAVI
In this new era of TAVI, there is a large role played 
by preprocedural assessment and imaging. The 
goals of preprocedural imaging are as follows:
1. Identify the patients with AS and confirm the 
severity.
2. Identifying patients suitable for TAVI.
3. Help in device selection (type and size) by 
defining the anatomic characteristics.
4. To develop a procedural plan (Vascular access/
fluoroscopic angulation).
The imaging methods vary among institution and 
individuals. ACC recently released expert consensus 
decision pathway for TAVI. The most commonly 
used imaging modalities are TTE, TEE, and CT scan.
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TTE is routinely used for initial assessment of 
aortic valve type, AS severity, and left ventricular 
function. TTE or TEE imaging can sometimes be 
limited in detection of BAV by factors such as 
patient body habitus and excessive calcification. 
Although a 3D TEE can improve the detection of 
BAV, it is not always feasible in seriously ill patients. 
Hayasida et al. reported disparity regarding the 
diagnosis of BAV between MDCT and TTE/TEE. 
In their study, MDCT detected BAV in 21 patients 
(9.2%), but TTE/TEE was able to pick only nine out 
the 21 cases.[39]
Given the favorable data coming out for TAVI in 
high-risk population,[45] TAVI is being evaluated 
in the intermediate risk group. This risk group 
includes younger patients, whose frequency of 
BAV is higher than the elderly.[46] With more BAV 
patients undergoing TAVI, there is a larger role 
for pre-procedural imaging to identify various 
anatomic as well as high-risk properties. This is 
achieved by a three-dimensional assessment of 
annular dimensions, which is commonly obtained 
by MDCT.[47,48]
MDCT helps in precise characterization of leaflet 
morphology, assessment of the symmetry of the 
aortic valve leaflets, and distribution of valvular 
calcification. All these mentioned factors are useful 
in selecting the type and size of the THV. MDCT 
also provides other anatomic information such as 
assessment of the left ventricular outflow tract, 
aortic root (“sinus of Valsalva”), determination of 
coronary heights, and identification of concomitant 
ascending aortopathy.
There are several classifications for BAV proposed 
earlier based on the pathological findings and 
echocardiography of which Sievers being the most 
popular one (e.g., Sievers et al. and Michelena 
et al.) [Table 2]. Most of the studies showed a 
high incidence of Sievers type 1 BAV.[1,44] Each 
type of BAV has unique anatomic features which 
may affect the outcomes of TAVI. Mylotte et al. 
described higher rates of post-implantation aortic 
regurgitation in Sievers type 1 (34.2%) compared 
to Sievers type 0 (13.3%).[29] In the advent of TAVI 
becoming more popular and widely used, there 
is a need for an alternative classification which 
can predict TAVI outcomes in BAV population. In 
the process, Jilaihawi et al. proposed a the TAVI-
Specific BAV classification using cardiac computed 
tomography analyzed by corelab (cedars-Sinai 
heart institute) to aid in pre-procedural planning 
in patients with BAV who are being evaluated for 
TAVI.[49] The MDCT images in 91 of 130 patients 
were reviewed and a novel classification was 
proposed in an effort to predict procedural 
outcomes after TAVI. The classification is depicted 
in Figure 1.
Here, they came up with a simplified TAVI directed 
classification based on the leaflet morphologies 
and orientation.
The specified three morphologies of BAV
1. Tricommisural (23.3%) – here one commissure 
is completely fused between two cusps, also 
known as functional or acquired type)
2. Bicommissural raphe type(55.6%) – here two 
cusps are fused (usually a or proximal to the 
basal third of the sinus) by a fibrous or calcified 
ridge of various heights, does not reach the 
height of the commissure
3. Bicommissural non-raphe type (21.1%) – the 
two cusps are completely fused from their 
basal origin by no visible seam here you see, 
only two commissures with no raphe or third 
commissure.
The leaflet orientation was divided based on the 
cusp fusion into:
1. Coronary cusp fusion – comparable to Sievers 
left-right for raphe type or anteroposterior for 
non-raphe type
2. Mixed noncoronary – coronary cusp fusion – 
comparable with Sievers right-non or non- Left 
for raphe type or lateral for non-raphe type (1).
They found no difference in overall rates of 30-
day mortality (3.8%), rates of moderate to severe 
AR (19% vs. 19.5% vs. 15%), the rate for new 
pacemakers and cerebrovascular events (3.2%) 
among anatomical subsets. The lack of outcomes 
correlation compared to Sievers classification 
(1), calls for an expansion of Jilaihawi et al.’s 
morphological classification. Assessment of the 
length of the raphe, the extent of calcification 
along the raphe could be important in predicting 
the outcomes of BAV TAVI.
One more important finding of Jilaihawi et al. 
was that the incidence of perivalvular aortic 
regurgitation (PAR) > moderate was 18.1% overall, 
but it was lower in patients who got a pre-procedural 
CT (11.5%). Predictors of post-procedural aortic 
regurgitation included intercommissural distance 
for bicommissural BAV and lack of baseline CT sizing 
before the procedure. This further emphasized the 
need for pre-procedural imaging for better sizing 
and anatomic definition of the valve, which further 
helps in better outcomes.[49]
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Back to the Case
Based on CT scan finding, we decided to use 
26 mm Evolut R valve for our patient. We accessed 
the common femoral artery with the help of 
fluoroscopy and ultrasound guidance. 26 mm 
Evolut R valve was advanced into the LV. We 
noticed complete heart block, so we decided to 
pace at 80 bpm. We attempted two deployments, 
but the valve would dive in at the level of the left 
coronary into the LVOT. We decided to attempt 
Table 2: Different classifications of BAV
Author (Ref. #) Specimens/Imaging test Number 
of Cases
Criteria Types
Roberts et al.[17] Surgical specimens 59 Cusp orientation Anterior-posterior cusps
Left-right cusps
Sabet et al.[3] Pathology 534 Raphe orientation RCC and LCC Fusion
RCC and NCC fusion
LCC and RCC fusion
Relative cusp size/
volume
Equal cusps
Unequal cusps
Thirds
Sievers et al.[1] Pathology 304 Number of raphae Type 0 (none)
Type 1 (one)
Type 2 (two)
Spatial position of 
raphe/cusp
Anterior-posterior cusps
Lateral cusps
RCC and LCC fusion
RCC and NCC fusion
LCC and NCC fusion
Functional status 
of the valve
Stenosis
Insufficiency
Both
None
Michelena et al.[11] Echocardiogram — Location of the 
commissures
Type 1: LCC and RCC fusion
Type 2: RCC and NCC fusion
Type 3: LCC and NCC fusion
Cusp symmetry Symmetric
Nonsymmetrical
Jilaihawi et al.[49] MDCT 91 Leaflet 
morphology
Tricommissural
Bicommissural non-raphe type
Bicommissural raphe type
Leaflet orientation Coronary cusp fusion
Coronary/noncoronary cusp 
fusion
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a third time with similar results. Even though we 
were not completely satisfied with the position 
of the valve; we had to deploy the valve as the 
patient became hemodynamically unstable. TEE 
revealed moderate PVL. The valve was post dilated 
the valve with a 20 mm true balloon. The BAV 
improved the expansion of the valve; however, 
there was still significant PVL. We decided to 
obtain right ulnar access (the radial artery had a 
loop and was occluded from a previous cath). We 
advanced a JR4 catheter an using a 10 mm Cook 
GooseNeck snare; we were able to snare one of 
the plates of the valve and slowly pulled back 
to a position where we achieved trivial PVL. We 
then noticed contrast stagnation and a contrast 
stain in the non-coronary cusp. We suspected a 
localized dissection of the non-coronary cusp. 
The patient became hypotensive and repeat 
CINE showed double contrast of the cardiac 
border. We confirmed this finding with TEE and 
performed pericardiocentesis with the removal 
of approximately 400 cc of blood. The patient 
also received permanent pacemaker for complete 
heart block.
The patient was transferred to CCU in a 
hemodynamically stable condition. The patient 
became anuric and developed acute tubular necrosis 
from hypotension during the procedure. She initially 
required CVVHD for acute renal failure. Hospital 
course was further complicated by pneumonia 
and septic shock. The patient briefly required 
vasopressors for sepsis, but her pneumonia and 
sepsis improved with broad-spectrum antibiotics. 
Her renal function recovered completely and she 
no longer required CVVHD. She was transferred to 
the floor after 4 days in CCU. The patient improved 
dramatically and eventually discharged to inpatient 
rehab at a facility near her house. With subsequent 
follow-up, she is doing well and her symptoms of AS 
improved significantly.
Conclusion
With the available observational data, it seems that 
TAVI is indeed technically feasible in selected BAV 
patients with acceptable results, especially with 
new-generation devices. Most of the current data 
studies highlight the importance of preprocedural 
imaging (esp. MDCT) determining the outcome 
of TAVI in BAV patients. To further evaluate the 
role of TAVI in the BAV patients, we would need 
to follow the standards set by the PARTNER trial, 
which suggested the role of TAVI in the treatment 
of high risk and inoperable patients with TAS. More 
research into the subject involving more clinical 
trials should be done to compare the success rate 
and efficiency between TAVI and SAVR.
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